Overview
Hemas is a diversified Sri Lankan group spanning healthcare, consumer brands, mobility, leisure, travel, aviation, logistics and maritime services. Healthcare includes pharmaceutical distribution, manufacturing and hospitals, while consumer operations include home and personal care and Atlas education products.
The most important recent change is that stronger sales did not translate into stronger profit in the September quarter: operating earnings improved, but higher costs below operations left net profit lower. This makes the quality of margin recovery, rather than sales growth alone, central to the current assessment.
Price performance
The voting share closed at LKR 32.80 on 17 November 2026. It fell 8.9% over one year versus a 7.7% fall in the ASPI, so the longer-term return lagged the broader market despite a recent recovery.
The price sat 56.5% of the way through its 52-week range. Recent volatility was below Hemas's own annual norm, while trading volume ran above its recent norm. The three-year record contains two falls of 15% or more; the deepest was 24% and took seven months to recover. Median daily turnover was LKR 5.2 million, and a LKR 1 million order is about 19% of what trades on a typical day, a noticeable part of a day's trading.
Valuation
At 11.4 times earnings for the twelve months to September 2026, the share price represents LKR 11.40 paid for each LKR 1 of trailing profit. This is at the cheap end of the diversified-holdings peer group, with its P/E at the 21st percentile among peers with available earnings multiples.
The P/B of 1.71 means the market pays LKR 1.71 for each LKR 1 of net assets, while trailing return on equity was 14.9%. P/B is more expensive than 76% of days since January 2019, even as P/E is cheaper than 57% of days over that period, so the current valuation relies more on earnings than on an unusually low price against book value.
The 3.0% dividend yield is supported by a LKR 1.00 trailing payout, up from LKR 0.90 in FY2025. A buyer at this price is relying on the latest quarter for 23.4% of trailing EPS; at the year-ago net margin, the P/E would be 10.9 times rather than 11.4 times.
News and sentiment
Coverage was about normal, with 21 material articles in the past 90 days: seven positive, 10 negative and four neutral. The dominant company-specific news was the September-quarter result reported on 6 November, where revenue growth and EBITDA recovery were offset by finance costs and margin pressure.
Hemas completed the acquisition of a 75% stake in Kenya's Twiga Stationers and Printers for US$16.2 million, reported on 18 August. The deal adds an East African platform for Atlas Axillia and consumer brands, but its revenue and profit contribution were not disclosed, so its near-term earnings effect cannot be sized from the available terms. The LKR 0.25 first interim dividend went ex on 16 November and is payable on 4 December.
Financials
September-quarter revenue grew 17.1% year-on-year and operating profit rose 8.1%, but net profit fell 1.7%. Gross margin was 29.7% versus 32.8% a year earlier, operating margin was 10.0% versus 10.8%, and net margin was 5.6% versus 6.7%. The group retained about 6 cents of profit from each LKR 1 of sales, down from nearly 7 cents a year earlier.
The September net margin ranked third of eight comparable September quarters, making it middling rather than an unusually weak historical result. However, LKR 1.7 billion was absorbed below operating profit through finance costs, tax, associates and other items, explaining why an operating gain did not reach shareholders as higher net earnings.
Equity rose to LKR 59.6 billion from LKR 51.7 billion a year earlier. Shares outstanding were broadly unchanged at 3.0 billion, so the year-on-year operating and profit changes are not primarily mechanical effects of a share-count change. Minority interests received 4.0% of annual profit, meaning group profit is slightly larger than the profit attributable to the ordinary shares being valued.
Risks
The leading risk is that finance and working-capital costs continue to dilute operating progress. September finance costs were LKR 464 million, up 149.4% year-on-year, and the resulting LKR 1.7 billion below-operating-profit drag was larger than the increase in operating profit.
The latest audited balance sheet was nevertheless conservatively financed: gearing was 10.8% of owners' equity, interest cover was 13.79 times, and net cash was LKR 11.6 billion. It had LKR 1.72 of current assets, including inventory and customer receivables, for each LKR 1 of bills due within a year, so short-term obligations were covered.
Cash conversion was 0.83 times in the year to March 2026, down from 0.98 times. Operating profit therefore did not fully arrive as cash, which matters while the group funds expansion and integration of Twiga. Healthcare represented 62% of reported segment revenue, making this the largest exposure to the healthcare operating environment.
Outlook
As at 18 November 2026, the next company-specific milestone is the interim filing for the quarter ending 31 December 2026, expected between 6 and 14 February 2027. It will show whether the September gap between operating profit and net profit was narrowed or extended, and whether the Twiga acquisition has begun to contribute measurable earnings.
The LKR 0.25 interim dividend is already ex, so a buyer after 16 November does not receive it. The available data cannot yet quantify Twiga's contribution or separate the persistence of margin pressure from the one-quarter finance-cost increase.